These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 19955186

  • 1. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
    Michael M, Antoniades M, Lemesiou E, Papaminas N, Melanthiou F.
    Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
    Campione E, Diluvio L, Paternò EJ, Di Marcantonio D, Francesconi A, Terrinoni A, Orlandi A, Chimenti S.
    Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
    Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P.
    J Assoc Physicians India; 2005 Apr; 53():291-5. PubMed ID: 15987013
    [Abstract] [Full Text] [Related]

  • 8. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S.
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [Abstract] [Full Text] [Related]

  • 9. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
    Scheinfeld N.
    J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
    [Abstract] [Full Text] [Related]

  • 10. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
    Tamura T, Tasaka T, Fujimoto M, Matsuhashi Y, Fukumot T, Mano S, Kuwajima M, Nagai M.
    Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
    [No Abstract] [Full Text] [Related]

  • 11. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C, Sattler M.
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [Abstract] [Full Text] [Related]

  • 12. Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
    Ferrand H, Tamburini J, Mouly S, Bouscary D, Bergmann JF.
    Clin Infect Dis; 2005 Dec 01; 41(11):1684-5. PubMed ID: 16267747
    [No Abstract] [Full Text] [Related]

  • 13. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
    Thierry A, Dreyfus B, Bridoux F, Abou Ayache R, Milin S, Guilhot F, Touchard G.
    Nephrol Dial Transplant; 2007 Jun 01; 22(6):1791-2. PubMed ID: 17308316
    [No Abstract] [Full Text] [Related]

  • 14. Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
    Srinivas U, Pillai LS, Kumar R, Pati HP, Saxena R.
    Am J Hematol; 2007 Apr 01; 82(4):314-6. PubMed ID: 17013815
    [Abstract] [Full Text] [Related]

  • 15. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
    Kim M, Lee S, Jung CK, Lim J, Cho SG, Kim DW, Kim Y, Han K, Min WS, Kim CC.
    Int J Lab Hematol; 2008 Dec 01; 30(6):508-12. PubMed ID: 18983302
    [Abstract] [Full Text] [Related]

  • 16. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J, Priwitzerová M, Jarosová M, Indrák K, Faber E, Divoký V.
    Cas Lek Cesk; 2006 Dec 01; 145(5):377-82. PubMed ID: 16755775
    [Abstract] [Full Text] [Related]

  • 17. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
    Wong M, Sade S, Gilbert M, Klieb HB.
    Dermatol Online J; 2011 May 15; 17(5):4. PubMed ID: 21635826
    [Abstract] [Full Text] [Related]

  • 18. Irreversible sensorineural hearing loss due to Imatinib.
    Attili VS, Bapsy PP, Anupama G, Lokanatha D.
    Leuk Res; 2008 Jun 15; 32(6):991-2. PubMed ID: 18221994
    [Abstract] [Full Text] [Related]

  • 19. Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
    Vernon MR, Pearson L, Atallah E.
    J Clin Rheumatol; 2009 Aug 15; 15(5):267. PubMed ID: 19654496
    [No Abstract] [Full Text] [Related]

  • 20. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
    Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G.
    Arch Dermatol; 2005 Mar 15; 141(3):368-70. PubMed ID: 15781678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.